BriaCell Therapeutics Corp.

Listed Company

BCTXCIK 0001610820NasdaqEmerging GrowthPharmaceutical PreparationsA1CAFY ends Jul 31

Period

FY 2025

Revenue

—

Net Income

$-26.31M

Total Assets

$21.65M

Equity

$17.33M

Shares Out

7.25M

Op. Cash Flow

$-28.17M

Business

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing novel immunotherapies to treat cancer, with an emphasis on targeted whole-cell and personalized off-the-shelf approaches. Its primary product candidates include Bria-IMT (a GM-CSF–secreting whole-cell immunotherapy), Bria-OTS/Bria-OTS+ personalized off-the-shelf platforms, next-generation Bria-PROS+/Bria-BRES+ lines, and antibody/TILsRx programs through a majority-owned subsidiary. The company operates clinical development programs (including a pivotal Phase 3 Bria-IMT trial), outsources GMP manufacturing to contract manufacturers, and conducts trials and commercialization activities through U.S. and international regulatory channels, clinical site networks, and collaborations with CROs and biopharma partners.

Summary from filing dated 2025-10-16

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-07-31	FY 2024 2024-07-31	FY 2023 2023-07-31	FY 2022 2022-07-31	FY 2021 2021-07-31
Research and development expenses	21	27	15	8	2
General and administrative expenses	6	6	8	7	5
Total operating expenses	27	33	23	—	—
Operating loss	−27	−33	−23	−15	−7
Financial income (expenses), net	114,511	262,566	850,340	−12	—
Change in fair value of the warrant liability	758,364	28	2	—	—
Share of loss on equity investment	−224,212	−106,510	—	—	—
Net loss for the year	−27	−5	−20	—	—
Net loss attributable to non-controlling interest	−244,273	−140,082	—	—	—
Net loss for the year attributable to BriaCell	−26	−5	−20	−27	−14
Net loss per share attributable to BriaCell - basic	−62.19	−43.68	−1.3	−1.73	−3.06
Net loss per share attributable to BriaCell - diluted	−62.19	−43.68	−1.3	−1.73	—
Weighted average number of shares (*) used in computing net loss per share attributable to ordinary shareholders, basic	423,114	109,699	16	15	5
Weighted average number of shares (*) used in computing net loss per share attributable to ordinary shareholders, diluted	423,114	109,699	16	15	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-07-31	FY 2024 2024-07-31	FY 2023 2023-07-31	FY 2022 2022-07-31	FY 2021 2021-07-31
Cash and cash equivalents	10	862,089	21	41	57
Short-term investments	7	—	—	—	—
Amounts receivable and prepaid expenses	2	3	6	—	—
Total current assets	20	4	27	42	58
Equity investment in BC Therapeutics	524,278	418,490	—	—	—
Intangible assets, net	184,525	199,796	215,068	—	—
Property and equipment, net	296,819	388,175	—	—	—
Long term prepaid expenses	717,508	1	—	—	—
Total non-current assets	2	2	215,070	230,341	245,612
Total assets	22	6	27	43	58
Trade payables	3	7	1	463,280	214,116
Accrued expenses and other payables	694,285	290,376	677,718	477,807	342,679
Total current liabilities	4	7	2	941,087	556,795
Warrant liability	337,672	1	29	—	—
Total non-current liabilities	337,672	1	29	31	30
CONTINGENT LIABILITIES AND COMMITMENTS	—	—	—	—	—
Share Capital of no par value Authorized: unlimited at July 31, 2025 and 2024; Issued and outstanding: 1,883,906 and 121,907 shares at July 31, 2025 and 2024, respectively	102	72	70	66	55
Share-based payment reserved	10	9	7	—	—
Warrant reserve	18	2	—	—	—
Accumulated other comprehensive loss	−138,684	−138,684	−138,684	−138,684	−138,684
Non-controlling interest	−546,795	−302,522	—	—	—
Accumulated deficit	−112	−85	−81	−60	−29
Total shareholders equity (deficit)	17	−3	−4	10	—
Total liabilities and shareholders equity (deficit)	22	6	27	43	58

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-07-31	FY 2024 2024-07-31	FY 2023 2023-07-31	FY 2022 2022-07-31	FY 2021 2021-07-31
Amortization	15,271	15,271	15,271	15,272	—
Financial income (expenses), net	−56,473	—	—	—	—
Depreciation	91,356	68,626	—	—	—
Share-based compensation	776,879	2	2	3	2
Decrease (increase) in amounts receivable	733,629	−732,578	5,230	−11,530	9,941
Decrease in prepaid expenses	492,279	2	−4	−764,054	−100,984
(Decrease) increase in accounts payable	−4	6	660,459	249,164	−1
Increase (decrease) in accrued expenses and other payables	753,909	−387,339	199,911	135,128	−785,399
Net cash used in operating activities	−28	−24	−24	−12	−8
Purchase of property and equipment	—	−456,801	—	—	—
Purchase of short-term investments, net	−7	—	—	—	—
Equity investment in BC Therapeutics	−330,000	−225,000	—	—	—
Net cash used in investing activities	−8	−681,801	—	—	—
Proceeds from exercise of warrants	821,015	—	1,594	7	14
Proceeds from issuance of shares, net of issuance costs	45	4	4	—	—
Net cash provided by financing activities	45	4	4	−4	65
Increase in cash and cash equivalents	10	−20	−20	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro